Moderna (MRNA) Operating Leases (2018 - 2026)

Moderna (MRNA) has 9 years of Operating Leases data on file, last reported at $664.0 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $664.0 million, changed 0.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $664.0 million (changed 0.45% YoY), and the FY2025 annual result was $653.0 million, down 2.68% from the prior year.
• Operating Leases rose to $664.0 million in Q1 2026 per MRNA's latest filing, from $653.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $697.0 million in Q3 2023 and troughed at $79.0 million in Q3 2022.
• A 5-year average of $468.4 million and a median of $653.0 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases plunged 37.8% in 2022, then jumped 782.28% in 2023.
• A 5-year view of Operating Leases shows it stood at $92.0 million in 2022, then surged by 598.91% to $643.0 million in 2023, then rose by 4.35% to $671.0 million in 2024, then slipped by 2.68% to $653.0 million in 2025, then advanced by 1.68% to $664.0 million in 2026.
• Business Quant data shows MRNA's Operating Leases at $664.0 million in Q1 2026, $653.0 million in Q4 2025, and $677.0 million in Q3 2025.